When your immune system turns against your nerves, what happens to the body?

Health · Published 3 October 2026 Swipe more like this →

In short: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune condition where the body attacks the protective myelin sheaths surrounding peripheral nerves. Often mistaken for its acute sibling, Guillain-Barré syndrome, this chronic disorder causes progressive weakness and sensory loss, yet early intervention can significantly alter the long-term prognosis for patients.

CIDP is an autoimmune disorder characterized by the immune system misidentifying the myelin sheath—the fatty, insulating layer around nerve fibers—as a threat. This damage disrupts the electrical impulses traveling from the brain to the rest of the body, leading to symptoms like tingling, numbness, and gradual muscle weakness. While it is often compared to Guillain-Barré syndrome, the primary distinction lies in duration: GBS is typically an acute, short-term event, whereas CIDP is a chronic condition that persists over time.

The disease manifests in several ways, including progressive, recurrent, or monophasic patterns. While typical CIDP presents with symmetric weakness in both proximal and distal muscles, variants exist that may affect only motor functions or sensory perception. Diagnosis remains challenging due to the condition's rarity and heterogeneous presentation. Physicians typically look for symptoms lasting longer than eight weeks, often utilizing nerve conduction studies, electromyography, and lumbar punctures to confirm myelin damage or elevated protein levels in cerebrospinal fluid.

Treatment focuses on suppressing the immune response, with options including steroids, intravenous immunoglobulin, plasma exchange, and monoclonal antibody therapy. Research indicates that up to 80% of patients respond well to these therapies. Early diagnosis is critical; without intervention, one-third of patients may eventually require a wheelchair. While the exact trigger for CIDP remains unclear—with no established genetic link—the importance of prompt management is universally recognized to prevent irreversible axonal loss and maximize functional recovery.

Recent studies highlight that electrophysiological normalization can occur in about one-third of patients who achieve clinical remission off treatment, particularly when diagnosed and treated early. Although some variants involving specific autoantibodies, such as those targeting paranodal proteins like neurofascin-155, may prove resistant to standard therapies and require alternatives like Rituximab, the broader outlook for CIDP patients has improved significantly with modern medical management and physical therapy.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• When your immune system turns against your spinal cord, the results are often sudden.
• Why your longest nerves are the first to fail in peripheral neuropathy
• Why do symptoms of nerve damage often start in your feet and hands?
• Myelin attack leaves millions navigating an unpredictable nerves disease
• Infections can hijack your nerves, but the peripheral nervous system has a secret advantage.
• The Philadelphia chromosome: How a genetic swap changed the history of cancer treatment
• The hidden health cost of undiagnosed mood disorders
• COPD ranked fourth among global killers in 2021
• Choline is essential to eat, yet officially it is not a vitamin
• When leg veins fail, blood pools and pressure builds, but relief is often simple.
• Rice-water diarrhea can empty twenty litres a day
• A misfolded protein is spreading through deer herds across North America

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics